Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

  • Home
  • /
  • Cadila Healthcare
Join Channel
Consolidated Standalone

Zydus Lifesciences

₹957.9 -6.5 | 0.7%

Market Cap ₹96382 Cr.

Stock P/E 25.2

P/B 4.4

Current Price ₹957.9

Book Value ₹ 216.9

Face Value 1

52W High ₹1323.9

Dividend Yield 0.31%

52W Low ₹ 666.3

Edit Ratio

Zydus Lifesciences Research see more...

Overview Inc. Year: 1995Industry: Pharmaceuticals & Drugs

Zydus Lifesciences Limited engages within the research, development, production, advertising, distribution, and sale of pharmaceutical products in India, America, and across the world. It offers finished dosage human formulations comprising generics, branded generics, and strong point formulations, including biosimilars and vaccines; active pharmaceutical elements; animal healthcare products; and consumer well being products. The enterprise presents products within the therapeutic regions of ache control, neurology, liver disease, and different areas. It additionally gives consumer health merchandise, which includes SugarFree and Sugarlite; Complan; EverYuth, a range of skin care merchandise; Nycil, a prickly heat powder; Glucon-D glucose powder; Sampriti Ghee; Nutralite; and diverse different products. In addition, the company is developing tablets inside the regions of oncology, autoimmune disorder, nephrology, ophthalmology, inflammation, rheumatology, hepatology, infectious disease, and so forth. Further, it gives animal healthcare merchandise for diverse therapeutic areas, including anti-bacterial, NSAIDs, anti-mastitis, tonics, and hen vaccines. The corporation also engages within the retail pharmacy, and manpower supply and administration activities. The company was previously called Cadila Healthcare Limited and modified its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was incorporated in 1952 and is primarily based in Ahmedabad, India.

Read More..

Zydus Lifesciences Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Zydus Lifesciences Quarterly Results

#(Fig in Cr.) Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 3964 4006 4257 5011 5140 4369 4505 5534 6208 5237
Other Income 174 174 144 38 36 136 58 162 63 114
Total Income 4139 4179 4401 5048 5176 4505 4564 5696 6271 5351
Total Expenditure 3240 3319 3406 3755 3634 3305 3423 3909 4124 3821
Operating Profit 899 860 995 1293 1541 1200 1140 1787 2147 1530
Interest 34 35 33 28 18 9 20 35 32 25
Depreciation 181 182 182 179 180 184 195 205 215 234
Exceptional Income / Expenses -3 0 0 -601 -14 0 0 0 0 0
Profit Before Tax 681 643 780 486 1329 1007 926 1547 1900 1271
Provision for Tax 118 137 195 137 216 226 214 321 436 373
Profit After Tax 563 506 585 349 1113 781 712 1226 1464 898
Adjustments -44 17 38 -52 -26 20 78 -44 -44 13
Profit After Adjustments 518 523 623 297 1087 801 790 1182 1420 911
Adjusted Earnings Per Share 5.1 5.2 6.2 2.9 10.7 7.9 7.8 11.8 14.1 9.1

Zydus Lifesciences Profit & Loss

#(Fig in Cr.) Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
Net Sales 7224 8651 9427 9377 11905 13166 14253 14404 15110 17237 19547 21484
Other Income 86 57 117 147 133 209 117 75 391 475 369 397
Total Income 7310 8709 9543 9524 12038 13374 14370 14479 15501 17712 19917 21882
Total Expenditure 6031 6897 7097 7472 9058 10187 11473 11018 11935 13666 14248 15277
Operating Profit 1279 1811 2446 2051 2980 3187 2897 3460 3565 4047 5668 6604
Interest 118 68 53 63 111 196 342 186 127 130 81 112
Depreciation 201 287 292 373 539 599 697 670 713 723 764 849
Exceptional Income / Expenses -17 -10 -3 -0 0 -10 -364 -205 113 -604 -14 0
Profit Before Tax 942 1446 2099 1615 2331 2382 1495 2399 2838 2590 4809 5644
Provision for Tax 106 259 177 129 564 530 320 194 512 588 978 1344
Profit After Tax 836 1186 1921 1486 1766 1852 1176 2206 2326 2002 3831 4300
Adjustments -33 -36 13 2 9 -3 1 -72 2161 -42 28 3
Profit After Adjustments 804 1151 1934 1488 1776 1849 1177 2134 4487 1960 3860 4303
Adjusted Earnings Per Share 7.8 11.2 18.9 14.5 17.3 18.1 11.5 20.8 43.8 19.4 38.4 42.8

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 13% 11% 8% 10%
Operating Profit CAGR 40% 18% 12% 16%
PAT CAGR 91% 20% 16% 16%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 42% 28% 30% 12%
ROE Average 21% 16% 16% 22%
ROCE Average 25% 18% 16% 18%

Zydus Lifesciences Balance Sheet

#(Fig in Cr.) Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Shareholder's Funds 3439 4252 5699 6960 8745 10386 10376 12992 17000 17516 19830
Minority's Interest 144 169 136 156 191 1293 1335 1937 2054 2173 2272
Borrowings 1362 1150 896 2468 2555 3950 3215 610 362 0 0
Other Non-Current Liabilities 227 191 -160 -565 -433 -459 -361 -590 -556 -725 193
Total Current Liabilities 2814 3285 3461 5306 6072 7343 8269 7861 7827 5527 5340
Total Liabilities 7987 9047 10032 14325 17141 22513 22834 22810 26700 24494 27637
Fixed Assets 3124 3352 3748 5755 6483 12164 12231 12133 12189 11521 12369
Other Non-Current Assets 1425 1468 2004 2548 2428 1851 1888 1962 2250 2957 3767
Total Current Assets 3438 4227 4280 6022 8201 8498 8715 8716 12095 10008 11420
Total Assets 7987 9047 10032 14325 17141 22513 22834 22810 26700 24494 27637

Zydus Lifesciences Cash Flow

#(Fig in Cr.) Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Opening Cash & Cash Equivalents 677 613 738 837 1593 1590 779 1178 888 658 488
Cash Flow from Operating Activities 903 994 1894 1312 919 1282 2932 3294 2105 2689 3228
Cash Flow from Investing Activities -438 -465 -864 -2872 -974 -4239 -1012 -725 -1000 1535 -1475
Cash Flow from Financing Activities -529 -351 -935 2316 52 1885 -1528 -2548 -868 -4400 -1810
Net Cash Inflow / Outflow -64 178 95 756 -3 -1072 391 22 236 -177 -58
Closing Cash & Cash Equivalent 613 790 837 1593 1590 779 1178 1087 1107 488 413

Zydus Lifesciences Ratios

# Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Earnings Per Share (Rs) 7.85 11.24 18.89 14.53 17.34 18.05 11.49 20.84 43.82 19.37 38.36
CEPS(Rs) 10.13 14.39 21.62 18.15 22.51 23.93 18.28 28.08 29.68 26.92 45.68
DPS(Rs) 1.8 2.4 3.2 3.2 3.5 3.5 3.5 3.5 2.5 6 3
Book NAV/Share(Rs) 33.58 41.52 55.66 67.97 85.4 101.43 101.33 126.88 166.01 173.08 197.11
Core EBITDA Margin(%) 16.18 19.9 24.22 19.89 23.82 22.62 19.51 11.72 10.74 10.53 13.97
EBIT Margin(%) 14.38 17.17 22.37 17.53 20.42 19.58 12.89 8.96 10.03 8.02 12.89
Pre Tax Margin(%) 12.78 16.4 21.82 16.87 19.5 18.09 10.49 8.31 9.6 7.64 12.68
PAT Margin (%) 11.34 13.46 19.98 15.52 14.78 14.07 8.25 7.64 7.87 5.9 10.1
Cash Profit Margin (%) 14.07 16.72 23.02 19.42 19.28 18.61 13.13 9.96 10.28 8.03 12.12
ROA(%) 10.89 13.93 20.14 12.2 11.23 9.34 5.18 9.66 9.4 7.82 14.7
ROE(%) 26.2 30.85 38.62 23.47 22.5 19.36 11.32 18.88 15.51 11.6 20.52
ROCE(%) 17.67 23.21 28.6 16.52 18.55 15.89 10.02 14.38 15.3 13.64 24.9
Receivable days 51.71 56.38 63.29 76.72 83.72 99.21 97.49 42.92 39.94 41.75 46.37
Inventory Days 63.89 60.13 54.52 59.88 63.95 70.33 70.13 38.08 42.95 38.39 32.98
Payable days 118.58 129.81 163.78 170.06 171.49 167.94 170.61 189.45 166.64 145.8 147.51
PER(x) 26.16 30.96 16.78 30.51 21.83 19.2 23.25 21.16 7.96 25.37 26.2
Price/Book(x) 6.11 8.38 5.69 6.52 4.43 3.42 2.64 3.47 2.1 2.84 5.1
Dividend Yield(%) 0.88 0.69 1.01 0.72 0.92 1.01 1.31 0.79 0.72 1.22 0.3
EV/Net Sales(x) 3.21 4.35 3.63 5.23 3.6 3.25 2.41 3.39 2.57 2.92 5.16
EV/Core EBITDA(x) 18.12 20.76 14.01 23.91 14.38 13.44 11.87 14.11 10.88 12.44 17.78
Net Sales Growth(%) 13.63 19.76 8.96 -0.53 26.97 10.59 8.26 1.06 4.9 14.08 13.4
EBIT Growth(%) 8.48 42.73 42.16 -22.02 45.53 5.58 -28.73 40.74 14.68 -8.28 79.81
PAT Growth(%) 21.21 41.84 61.98 -22.67 18.89 4.83 -36.52 87.61 5.48 -13.95 91.39
EPS Growth(%) 22.97 43.18 68.08 -23.07 19.37 4.11 -36.36 81.34 110.32 -55.8 98.06
Debt/Equity(x) 0.79 0.62 0.43 0.75 0.62 0.76 0.77 0.35 0.25 0.07 0.04
Current Ratio(x) 1.22 1.29 1.24 1.14 1.35 1.16 1.05 1.11 1.55 1.81 2.14
Quick Ratio(x) 0.74 0.82 0.86 0.8 0.96 0.79 0.72 0.7 1.07 1.19 1.5
Interest Cover(x) 8.98 22.29 40.75 26.59 22.04 13.17 5.38 13.87 23.35 20.94 60.22
Total Debt/Mcap(x) 0.13 0.07 0.08 0.11 0.14 0.22 0.29 0.1 0.12 0.02 0.01

Zydus Lifesciences Shareholding Pattern

# Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Promoter 74.88 74.98 74.98 74.98 74.98 74.98 74.98 74.98 74.98 74.98
FII 2.86 2.6 2.51 3.42 4.04 4.86 5 5.72 5.59 7.52
DII 12.03 12.94 13.69 13.6 13.52 13.09 13.03 12.63 12.64 10.65
Public 10.24 9.48 8.81 8 7.47 7.07 6.99 6.66 6.8 6.85
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Company is almost debt free.

Cons

  • Debtor days have increased from 145.8 to 147.51days.
  • Stock is trading at 4.4 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Zydus Lifesciences News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!